Antibody-based drug discovery at the speed of light

Capabilities and technology combine to provide First-to-Human antibody discovery, development and clinical manufacturing. Speed, scientific expertise, and efficiency can surmount the high attrition rates of early antibody discovery and achieve first-to-market delivery of new therapeutics.

Download our white paper for insights on:
•    First-to-Human antibody therapeutics
•    Immunization — PentaMice®️ platform for antibody generation
•    Single B cell screening with the Beacon®️ system
•    Sequence Identification
•    Custom Bioinformatics
•    Case Study: Discovery of diverse monoclonal antibodies that bind SARS-CoV-2 Delta and Omicron spike proteins
•    Gene-to-Protein Strategies

Request Free!